Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis.
about
Effect of diet and omega-3 fatty acid intervention on asymmetric dimethylarginine.A novel model of chronic wounds: importance of redox imbalance and biofilm-forming bacteria for establishment of chronicityProteomics of human umbilical vein endothelial cells applied to etoposide-induced apoptosisThe Mechanism of and Preventive Therapy for Stroke in Patients with Atrial FibrillationAsymmetric dimethylarginine as a mediator of vascular dysfunction in cirrhosisInhibitors of the Hydrolytic Enzyme Dimethylarginine Dimethylaminohydrolase (DDAH): Discovery, Synthesis and DevelopmentNitric oxide and reactive oxygen species in the pathogenesis of preeclampsiaOral L-arginine improves endothelial function in healthy individuals older than 70 yearsPlasma asymmetric dimethylarginine modifies the effect of pravastatin on myocardial blood flow in young adultsTotal nitric oxide production is low in patients with chronic renal diseaseDimethylarginine dimethylaminohydrolase I enhances tumour growth and angiogenesisRoles of accumulated endogenous nitric oxide synthase inhibitors, enhanced arginase activity, and attenuated nitric oxide synthase activity in endothelial cells for pulmonary hypertension in ratsA functional variant of the dimethylarginine dimethylaminohydrolase-2 gene is associated with insulin sensitivityStructural and functional characterization of the Zn(II) site in dimethylargininase-1 (DDAH-1) from bovine brain. Zn(II) release activates DDAH-1.L-Arginine supplementation or arginase inhibition augments reflex cutaneous vasodilatation in aged human skin.Effects of chronic and acute consumption of fruit- and vegetable-puree-based drinks on vasodilation, risk factors for CVD and the response as a result of the eNOS G298T polymorphism.Postprandial vascular effects of VIAject compared with insulin lispro and regular human insulin in patients with type 2 diabetes.Platelet aggregation responses are critically regulated in vivo by endogenous nitric oxide but not by endothelial nitric oxide synthaseCurrent concepts in the diagnosis and classification of renal dysfunction in cirrhosis.Nitric oxide in the pathogenesis of vascular disease.Mechanisms of nitric oxide synthase uncoupling in endotoxin-induced acute lung injury: role of asymmetric dimethylarginine.Effects of metformin on endothelial health and erectile dysfunction.The Role of Asymmetric Dimethylarginine (ADMA) in Endothelial Dysfunction and Cardiovascular DiseaseCarotid intima-media thickness as a measure of vascular target organ damage.Optimization of the separation of NDA-derivatized methylarginines by capillary and microchip electrophoresis.Flow, NO, and atherogenesisAsymmetric dimethylarginine potentiates lung inflammation in a mouse model of allergic asthma.Effects of local gene transfer of VEGF on neointima formation after balloon injury in hypercholesterolemic rabbits.Helicobacter pylori eradication lowers serum asymmetric dimethylarginine levels.A systematic review of metabolite profiling in gestational diabetes mellitus.4-HNE increases intracellular ADMA levels in cultured HUVECs: evidence for miR-21-dependent mechanismsIndexes of NO bioavailability in human blood.L-arginine in cardiovascular disease: dream or reality?The pathophysiology of erectile dysfunction related to endothelial dysfunction and mediators of vascular function.Prediabetes mellitus and its links to atherosclerosis.Asymmetric dimethylarginine correlates with measures of disease severity, major adverse cardiovascular events and all-cause mortality in patients with peripheral arterial disease.Potential mechanisms of impaired endothelial function in arterial hypertension and hypercholesterolemia.Interaction of G-protein beta3 subunit and nitric oxide synthase gene polymorphisms on carotid artery intima-media thickness in young adults: the Bogalusa Heart Study.Biomarkers of peripheral arterial disease.Effects of L-arginine on flow mediated dilatation induced by atrial pacing in diseased epicardial coronary arteries.
P2860
Q21245073-C294D0F4-12D0-4904-91D0-7C8903B810EDQ21559454-DA4E487D-DC0A-497E-B9A1-37EFCAC434F1Q24318932-F033E7CD-BE06-4ECB-A918-4E891C04F8E5Q26747263-FDE9412D-6E23-4535-B338-8670BD1DD418Q26795604-665B405B-06D0-4D39-879F-87C50FD2CE9CQ28070134-6ED0DA33-ED29-49F4-B475-AE0CDBD1A697Q28083676-08B78312-470D-4CB4-B6E3-56647EB39CFAQ28205825-02740F82-00CF-4717-81C1-42096286D591Q28247348-A3F30DD4-F692-4DC4-99E5-F44CF99996B2Q28344716-519608B8-DA0E-4CDE-9C56-290C4C3817EEQ28578409-B5C1E945-D981-4F32-B95A-5FBA8B1A7BCCQ28578942-DD4DF247-0822-4675-A5D1-172F0A3681E9Q28730293-FD7F47E5-2738-4461-9F9C-452236DBFD81Q30328626-C166BA59-7AAB-469B-A1F0-04A7BD903CACQ33242325-3DEB3F9F-E4B1-40F4-90AC-40C7D313BDBDQ33418497-D4450E7F-9271-41A1-B06A-7276D53C3E7FQ33556716-FBFCD84E-3B80-430E-A2CB-200B7D859483Q33569525-D67D5840-BE98-4E5A-8372-15D71E74AE02Q33811643-CA1F8963-7EAC-448B-ADFD-E594A0978B60Q33843539-29DD8B4B-96CA-4D95-8A22-2CA03C726E48Q33889586-9D99BF8A-2D3B-44F0-9054-3808861B2DEEQ33890190-EDD4F7DB-B0AD-40E0-9C55-5DCF4C838390Q33940891-15E44F7E-F369-45EB-93D8-6B3D358952E3Q34028413-34204899-D646-4299-879F-C635A0400A39Q34167247-49505377-A4F9-467B-BB7C-98539C1D164CQ34327487-B1546F94-1BC6-4D53-A7F6-66037CA9763CQ34426054-36F8E24E-86AC-40F7-A571-D1EF47D9B538Q34429250-3F7F1907-D68F-47E2-A9CB-4549384D97B1Q34442956-A801174F-4409-492B-86A9-1E85EFACB31AQ34458995-EC46791C-7E76-48A2-97ED-C0BF5A380E93Q34745328-F5357442-96FA-4A5D-87EA-A49FC24A8B07Q34998608-08CA0B3F-3BD4-43A1-AE95-37B0AA1CAB7CQ35055189-2F99D665-B87E-46CD-B8D9-02809A69E282Q35055194-45895053-6488-40CC-AED9-BC453A639F4DQ35087456-DA358754-B427-4808-B1A1-6FBE8F9011D6Q35090446-828B6EE3-13B2-4C7B-B958-D5BD16C1C743Q35118290-D5845A49-13CB-4370-9DAC-D32A306218A0Q35144493-FAB52D9D-146E-45DE-A808-169CD9C7F428Q35170187-1C0C9E35-022A-4638-8C7B-0AE89652C941Q35581097-AF722E9C-B500-45B1-84A8-496D17908093
P2860
Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh-hant
name
Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis.
@en
Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis.
@nl
type
label
Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis.
@en
Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis.
@nl
prefLabel
Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis.
@en
Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis.
@nl
P2093
P356
P1433
P1476
Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis.
@en
P2093
H Matsuoka
H Miyazaki
T Imaizumi
P304
P356
10.1161/01.CIR.99.9.1141
P407
P577
1999-03-01T00:00:00Z